Viewing Study NCT05197192


Ignite Creation Date: 2025-12-24 @ 3:45 PM
Ignite Modification Date: 2026-01-06 @ 2:48 PM
Study NCT ID: NCT05197192
Status: RECRUITING
Last Update Posted: 2025-08-17
First Post: 2021-09-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
Sponsor: German CLL Study Group
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module